Insider Transaction: Lars Anderson Unloaded 16,485 Shares of Fifth Third Bancorp (FITB); Aimmune Therapeutics (AIMT) Shorts Decreased By 11.75%

Aimmune Therapeutics Incorporated (NASDAQ:AIMT) had a decrease of 11.75% in short interest. AIMT’s SI was 3.36 million shares in February as released by FINRA. Its down 11.75% from 3.81M shares previously. With 279,000 avg volume, 12 days are for Aimmune Therapeutics Incorporated (NASDAQ:AIMT)’s short sellers to cover AIMT’s short positions. The SI to Aimmune Therapeutics Incorporated’s float is 12.53%. The stock increased 0.74% or $0.28 during the last trading session, reaching $38.24. About 198,627 shares traded. Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has risen 32.49% since February 15, 2017 and is uptrending. It has outperformed by 15.79% the S&P500.

In view of the trade Lars Anderson made he is in the bear’s eye today. The EVP & Chief Operating Officer of Fifth Third Bancorp and an insider, sold 16,485 shares worth $530,570 US Dollars. The average price was $32.2 per share. he currently holds 0.03% of the market cap of the company.

Among 4 analysts covering Aimmune Therapeutics (NASDAQ:AIMT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aimmune Therapeutics had 5 analyst reports since August 31, 2015 according to SRatingsIntel. The firm has “Mkt Outperform” rating given on Monday, September 26 by JMP Securities. The stock of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) earned “Outperform” rating by Credit Suisse on Monday, August 31. As per Monday, August 31, the company rating was initiated by Piper Jaffray. The rating was maintained by Piper Jaffray with “Overweight” on Tuesday, November 17. The rating was initiated by Bank of America with “Buy” on Monday, August 31.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. The company has market cap of $1.96 billion. The Company’s lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. It currently has negative earnings. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics.

Since August 18, 2017, it had 0 insider purchases, and 2 insider sales for $678,998 activity. 7,500 shares were sold by Hazel Mark D, worth $246,098. Spence Timothy had sold 15,000 shares worth $432,900 on Thursday, October 26. On Friday, August 18 the insider Forrest Frank R. sold $183,540.

The stock decreased 0.15% or $0.05 during the last trading session, reaching $33.2. About 3.23 million shares traded. Fifth Third Bancorp (NASDAQ:FITB) has risen 33.30% since February 15, 2017 and is uptrending. It has outperformed by 16.60% the S&P500.

Fifth Third Bancorp operates as a diversified financial services firm in the United States. The company has market cap of $23.03 billion. It operates through four divisions: Commercial Banking, Branch Banking, Consumer Lending, and Wealth and Asset Management. It has a 11.73 P/E ratio. The Commercial Banking segment offers credit intermediation, cash management, and financial services; lending and depository products; and foreign exchange and international trade finance, derivatives and capital markets services, asset lending, real estate finance, public finance, commercial leasing, and syndicated finance for business, government, and professional customers.

Among 33 analysts covering Fifth Third (NASDAQ:FITB), 6 have Buy rating, 3 Sell and 24 Hold. Therefore 18% are positive. Fifth Third has $37.0 highest and $16 lowest target. $28.21’s average target is -15.03% below currents $33.2 stock price. Fifth Third had 103 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Bank of America given on Wednesday, January 24. As per Thursday, September 28, the company rating was maintained by Nomura. JP Morgan maintained Fifth Third Bancorp (NASDAQ:FITB) rating on Thursday, April 7. JP Morgan has “Neutral” rating and $19 target. As per Wednesday, January 24, the company rating was maintained by RBC Capital Markets. The stock has “Hold” rating by BMO Capital Markets on Friday, May 26. Oppenheimer maintained Fifth Third Bancorp (NASDAQ:FITB) on Friday, January 22 with “Outperform” rating. Nomura downgraded Fifth Third Bancorp (NASDAQ:FITB) on Monday, October 10 to “Reduce” rating. The stock of Fifth Third Bancorp (NASDAQ:FITB) earned “Underperform” rating by Macquarie Research on Friday, November 17. The stock of Fifth Third Bancorp (NASDAQ:FITB) earned “Buy” rating by RBC Capital Markets on Wednesday, October 25. The firm earned “Hold” rating on Tuesday, January 2 by Barclays Capital.

Investors sentiment decreased to 0.65 in 2017 Q3. Its down 0.16, from 0.81 in 2017Q2. It worsened, as 45 investors sold Fifth Third Bancorp shares while 234 reduced holdings. 48 funds opened positions while 134 raised stakes. 575.67 million shares or 0.33% more from 573.75 million shares in 2017Q2 were reported. Dekabank Deutsche Girozentrale has 0.01% invested in Fifth Third Bancorp (NASDAQ:FITB) for 66,803 shares. Bancshares Of America De invested in 0.01% or 3.32M shares. Riverhead Cap Mngmt Ltd Liability Corp reported 105,963 shares or 0.14% of all its holdings. San Francisco Sentry Investment Grp (Ca) holds 0% in Fifth Third Bancorp (NASDAQ:FITB) or 18 shares. The New York-based Bnp Paribas Arbitrage Sa has invested 0.03% in Fifth Third Bancorp (NASDAQ:FITB). Denver Invest Advsr Lc stated it has 0.1% of its portfolio in Fifth Third Bancorp (NASDAQ:FITB). First Citizens Bank & Trust Tru invested in 13,279 shares. Cullinan Associate holds 0.15% of its portfolio in Fifth Third Bancorp (NASDAQ:FITB) for 71,140 shares. Cambridge Invest Rech Advsr reported 40,241 shares. Breton Hill Cap has invested 0.38% in Fifth Third Bancorp (NASDAQ:FITB). Intrust Fincl Bank Na stated it has 0.15% of its portfolio in Fifth Third Bancorp (NASDAQ:FITB). Lazard Asset Mgmt Llc stated it has 0.01% of its portfolio in Fifth Third Bancorp (NASDAQ:FITB). Brown Advisory Inc owns 7,866 shares for 0% of their portfolio. Barrow Hanley Mewhinney And Strauss Ltd Liability invested in 7.37 million shares or 0.31% of the stock. Moreover, Lynch & In has 0.2% invested in Fifth Third Bancorp (NASDAQ:FITB).

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: